Advanced Search
Contact | Corporate | Help

Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects

Sponsors:
  • Achillion Pharmaceuticals
Phases:
  • Phase II
IndicationsAcronym:
  • Hepatitis C
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: ACH-0141625
  • Drug: ACH-0141625
  • Drug: ACH-0141625
  • Drug: Placebo
  • Drug: Pegylated Interferon alpha-2a
  • Drug: ribavirin
  • Drug: ACH-0141625 Dose TBD or placebo
Enrollment:
144

Additional information about NCT01180790.


SourceSolution © 2008-2012